Sona Nanotech Inc. (SONA.CN)

0.3750 -0.0400 (-9.64%) At close: 03:59PM EDT

Sona Nanotech Inc.

Purdy’s Wharf Tower II
Suite 2001 1969 Upper Water Street
Halifax, NS B3J 3R7
Canada
902 442 0653
https://www.sonanano.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. David Andrew Regan	Chief Executive Officer	260k	N/A	1969
Mr. Robert William George Randall CPA	CFO & Corporate Secretary	63.11k	N/A	1963
Dr. Len Pagliaro Ph.D.	CSO & Director	218.64k	N/A	N/A
Dr. Kulbir Singh Ph.D.	Co-Founder & Head of R&D	N/A	N/A	N/A
Dr. Mike McAlduff	Director of R&D & Production and Founder	N/A	N/A	N/A
Dr. Gerrard Marangoni	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Darren Rowles	Head of Diagnostics	189k	N/A	1979

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Sona Nanotech Inc. operates as a nanotechnology life sciences company. It develops targeted hyperthermia therapy for cancer treatment; and nanomedical therapy for the treatment of colorectal cancer. The company also develops gold nanoparticle products; lateral flow assay rapid tests; bovine TB tests; and concussion screening tests. Sona Nanotech Inc. was founded in 2013 and is based in Halifax, Canada.

Corporate Governance

Sona Nanotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.